Angiodrastic Chemokines Production by Colonic Cancer Cell Lines
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
- (a)
- Only patients with stages II and III according to TNM classification (stages B and C according to Dukes classification, as modified by Astler-Coller) were included. Metastatic disease (type IV) patients were excluded.
- (b)
- Only patients with a curative (R0) surgical resection who did not receive adjuvant chemotherapy (either refused or were not considered as candidates by the attending doctors) were selected.
2.1. Cell Cultures
2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
2.3. Statistics
3. Results
3.1. Measurements over Time
3.1.1. HT-29—CXCL8
3.1.2. HT-29—CXCL6
3.1.3. HT-29—CXCL4
3.1.4. HT-29—VEGF
3.1.5. Caco-2—CXCL8
- Overall, there was a significant difference only at 4, 6, and 12 h (p < 0.05).
3.1.6. Caco-2—CXCL6
3.1.7. Caco-2—CXCL4
- Overall, significant differences existed at all time points (p < 0.05).
3.1.8. Caco-2—VEGF
3.2. Measurements over Time
3.2.1. CXCL8—Ca Serum
3.2.2. CXCL8—Normal Serum
3.2.3. CXCL6—Ca Serum
3.2.4. CXCL6—Normal Serum
3.2.5. CXCL4—Ca Serum
3.2.6. CXCL4—Normal Serum
3.2.7. VEGF—Ca Serum
3.2.8. VEGF—Normal Serum
4. Discussion
4.1. Do HT-29 and Caco-2 Cells Produce Angiodrastic Cytokines in Basal Conditions?
4.2. Are There Differences between HT-29 and Caco-2 Cells?
4.3. Is There a Difference in the Time Course Response between Cancer and Normal Serum Incubation?
4.4. Functional Significance of the Findings
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Herszenyi, L.; Tulassay, Z. Epidemiology of gastrointestinal and liver tumors. Eur. Rev. Med. Pharmacol. Sci. 2010, 14, 249–258. [Google Scholar] [PubMed]
- Hemmings, C. Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis. Pathology 2013, 45, 371–381. [Google Scholar] [CrossRef] [PubMed]
- Emmanouil, G.; Ayiomamitis, G.; Zizi-Sermpetzoglou, A.; Tzardi, M.; Moursellas, A.; Voymvouraki, A.; Kouroumalis, E. Angiodrastic Chemokines in Colorectal Cancer: Clinicopathological Correlations. Anal. Cell. Pathol. 2018, 2018, 1616973. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fogh, J.; Trempe, G. New human tumor cell lines. In Human Tumor Cell In Vitro, 1st ed.; Fogh, J., Ed.; Springer: New York, NY, USA, 1975; pp. 115–159. [Google Scholar] [CrossRef]
- Fogh, J.; Wright, J.C.; Loveless, J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumours. J. Natl. Cancer Inst. 1977, 58, 209–214. [Google Scholar] [CrossRef]
- Strieter, R.M.; Polverini, P.J.; Kunkel, S.L.; Arenberg, D.A.; Burdick, M.D.; Kasper, J.; Dzuiba, J.; van Damme, J.; Walz, A.; Marriott, D.; et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 1995, 270, 27348–27357. [Google Scholar] [CrossRef] [Green Version]
- Bonecchi, R.; Galliera, E.; Borroni, E.M.; Corsi, M.M.; Locati, M.; Mantovani, A. Chemokines and chemokine receptors: An overview. Front. Biosci. (Landmark Ed.) 2009, 14, 540–551. [Google Scholar] [CrossRef] [Green Version]
- Sturm, A.; Baumgart, D.C.; d’Heureuse, J.H.; Hotz, A.; Wiedenmann, B.; Dignass, A.U. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine 2005, 29, 42–48. [Google Scholar] [CrossRef]
- Cui, G.; Yuan, A.; Goll, R.; Vonen, B.; Florholmen, J. Dynamic changes of interleukin-8 network along the colorectal adenoma-carcinoma sequence. Cancer Immunol. Immunother. 2009, 58, 1897–1905. [Google Scholar] [CrossRef]
- Ning, Y.; Manegold, P.C.; Hong, Y.K.; Zhang, W.; Pohl, A.; Lurje, G.; Winder, T.; Yang, D.; LaBonte, M.J.; Wilson, M.L.; et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int. J. Cancer 2010, 128, 2038–2049. [Google Scholar] [CrossRef] [Green Version]
- Strieter, R.M.; Polverini, P.J.; Arenberg, D.; Kunkel, S.L. The role of CXC chemokines as regulators of angiogenesis. Shock 1995, 4, 155–160. [Google Scholar] [CrossRef]
- Vandercappellen, J.; van Damme, J.; Struyf, S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008, 267, 226–244. [Google Scholar] [CrossRef] [PubMed]
- Wuyts, A.; van Osselaer, N.; Haelens, A.; Samson, I.; Herdewijn, P.; Ben-Baruch, A.; Oppenheim, J.J.; Proost, P.; van Damme, J. Characterization of synthetic human granulocyte chemotactic protein 2: Usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. Biochemistry 1997, 36, 2716–2723. [Google Scholar] [CrossRef] [PubMed]
- Heidemann, J.; Ogawa, H.; Dwinell, M.B.; Rafiee, P.; Maaser, C.; Gockel, H.R.; Otterson, M.F.; Ota, D.M.; Lugering, N.; Domschke, W.; et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 2003, 278, 8508–8515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maione, T.E.; Gray, G.S.; Petro, J.; Hunt, A.J.; Donner, A.L.; Bauer, S.I.; Carson, H.F.; Sharpe, R.J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247, 77–79. [Google Scholar] [CrossRef]
- Gupta, S.K.; Singh, J.P. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J. Cell Biol. 1994, 127, 1121–1127. [Google Scholar] [CrossRef]
- Shellenberger, T.D.; Wang, M.; Gujrati, M.; Jayakumar, A.; Strieter, R.M.; Burdick, M.D.; Ioannides, C.G.; Efferson, C.L.; El-Naggar, A.K.; Roberts, D.; et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 2004, 64, 8262–8270. [Google Scholar] [CrossRef] [Green Version]
- Struyf, S.; Burdick, M.D.; Proost, P.; van Damme, J.; Strieter, R.M. Platelets release CXCL14L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ. Res. 2004, 95, 855–857. [Google Scholar] [CrossRef]
- Kowanetz, M.; Ferrara, N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin. Cancer Res. 2006, 12, 5018–5022. [Google Scholar] [CrossRef] [Green Version]
- Aldebasi, Y.; Rahmani, A.; Khan, A.; Aly, S. The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy. Int. J. Clin. Exp. Med. 2013, 6, 239–251. [Google Scholar]
- Tchaikovski, V.; Fellbrich, G.; Waltenberger, J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arter. Thromb. Vasc. Biol. 2008, 28, 322–328. [Google Scholar] [CrossRef] [Green Version]
- Kucharzik, T.; Hudson, J.T., III; Lugering, A.; Abbas, J.A.; Bettini, M.; Lake, J.G.; Evans, M.E.; Ziegler, T.R.; Merlin, D.; Madara, J.L.; et al. Acute induction of human IL-8 production by intestinal epithelium triggers neutrophil infiltration without mucosal injury. Gut 2005, 54, 1565–1572. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, H.Y.; Sneddon, J.B.; Alizadeh, A.A.; Sood, R.; West, R.B.; Montgomery, K.; Chi, J.-T.; van De Rijn, M.; Botstein, D.; O Brown, P. Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol. 2004, 2, e7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, H.Y.; Nuyten, D.S.A.; Sneddon, J.B.; Hastie, T.; Tibshirani, R.; Sørlie, T.; Dai, H.; He, Y.D.; Veer, L.J.V.; Bartelink, H.; et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 2005, 102, 3738–3743. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huet, C.; Sahuquillo-Merino, C.; Coudrier, E.; Louvard, D. Absorptive and mucus-secreting subclones isolated from a multipotent intestinal cell line (HT-29) provide new models for cell polarity and terminal differentiation. J. Cell Biol. 1987, 105, 345–357. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Desai, S.; Kumar, A.; Laskar, S.; Pandey, B.N. Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine 2013, 61, 54–62. [Google Scholar] [CrossRef] [PubMed]
- Kelly, C.P.; Keates, S.; Siegenberg, D.; Linevsky, J.K.; Pothoulakis, C.; Brady, H.R. IL-8 secretion and neutrophil activation by HT-29 colonic epithelial cells. Am. J. Physiol.-Gastrointest. Liver Physiol. 1994, 267, G991–G997. [Google Scholar] [CrossRef]
- Schuerer-Maly, C.C.; Eckmann, L.; Kagnoff, M.F.; Falco, M.T.; Maly, F.E. Colonic epithelial cell lines as a source of interleukin-8: Stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology 1994, 81, 85–91. [Google Scholar]
- Kolios, G.; Wright, K.L.; Jordan, N.J.; Leithead, J.B.; Robertson, D.A.; Westwick, J. C-X-C and C-C chemokine expression and secretion by the human colonic epithelial cell line, HT-29: Differential effect of T lymphocyte-derived cytokines. Eur. J. Immunol. 1999, 29, 530–536. [Google Scholar] [CrossRef]
- Wang, Y.L.; Fang, M.; Wang, X.M.; Liu, W.Y.; Zheng, Y.J.; Wu, X.B.; Tao, R. Proinflammatory effects and molecular mechanisms of interleukin-17 in intestinal epithelial cell line HT-29. World J. Gastroenterol. 2014, 20, 17924–17931. [Google Scholar] [CrossRef]
- Zhang, M.; Wang, G.; Tao, Y.; Zhang, H. The proinflammatory effect and molecular mechanism of IL-17 in the intestinal epithelial cell line HT-29. J. BUON 2015, 20, 120–127. [Google Scholar]
- Schaffner, P.; Rhyn, G.; Schoedon, D.J. Schaer, Regulated expression of platelet factor 4 in human monocytes-role of PARs as a quantitatively important monocyte activation pathway. J. Leukoc. Biol. 2005, 78, 202–209. [Google Scholar] [CrossRef] [PubMed]
- Mauritz, I.; Westermayer, S.; Marian, B.; Erlach, N.; Grusch, M.; Holzmann, K. Prostaglandin E(2) stimulates progression-related gene expression in early colorectal adenoma cells. Br. J. Cancer 2006, 94, 1718–1725. [Google Scholar] [CrossRef] [PubMed]
- Li, A.; Varney, M.L.; Singh, R.K. Expression of Interleukin 8 and Its Receptors in Human Colon Carcinoma Cells with Different Metastatic Potentials. Clin. Cancer Res. 2001, 7, 3298–3304. [Google Scholar] [PubMed]
- Dimberg, J.; Ström, K.; Löfgren, S.; Zar, N.; Lindh, M.; Matussek, A. DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas. Int. J. Color. Dis. 2011, 27, 709–714. [Google Scholar] [CrossRef] [Green Version]
- Xu, B.; Wang, Y.; Yang, J.; Zhang, Z.; Zhang, Y.; Du, H. Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo. Cancer Chemother. Pharmacol. 2016, 77, 797–806. [Google Scholar] [CrossRef]
- Manousou, P.; Kolios, G.; Drygiannakis, I.; Pyrovolaki, K.; Bourikas, L.; Papadaki, H.A.; Kouroumalis, E. Expression of a splice variant of CXCR3 in Crohn’s disease patients; Indication for a lymphocyte—Epithelial cell interaction. J. Gastroenterol. Hepatol. 2008, 23, 1823–1833. [Google Scholar] [CrossRef]
- O’Sullivan, F.; Keenan, J.; Aherne, S.; O’Neill, F.; Clarke, C.; Henry, M.; Meleady, P.; Breen, L.; Barron, N.; Clynes, M.; et al. Parallel mRNA, proteomics and miRNA expression analysis in cell line models of the intestine. World J. Gastroenterol. 2017, 23, 7369–7386. [Google Scholar] [CrossRef]
- Biasi, F.; Tessitore, L.; Zanetti, D.; Cutrin, J.C.; Zingaro, B.; Chiarpotto, E.; Zarkovic, N.; Serviddio, G.; Poli, G. Associated changes of lipid peroxidation and transforming growth factor beta1 levels in human colon cancer during tumour progression. Gut 2002, 50, 361–367. [Google Scholar] [CrossRef] [Green Version]
- Zanetti, D.; Poli, G.; Vizio, B.; Zingaro, B.; Chiarpotto, E.; Biasi, F. 4-hydroxynonenal and transforming growth factor-beta1 expression in colon cancer. Mol. Asp. Med. 2003, 24, 273–280. [Google Scholar] [CrossRef]
- Brew, R.; Erikson, J.S.; West, D.C.; Kinsella, R.A.; Slavin, J.; Christmas, S.E. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 2000, 12, 78–85. [Google Scholar] [CrossRef]
- Lee, Y.S.; Choi, I.; Ning, Y.; Kim, N.Y.; Khatchadourian, V.; Yang, D.; Chung, H.K.; Choi, D.; LaBonte, M.J.; Ladner, R.D.; et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br. J. Cancer 2012, 106, 1833–1841. [Google Scholar] [CrossRef] [PubMed]
- Alfaro, C.; Teijeira, A.; Oñate, C.; Pérez, G.; Sanmamed, M.F.; Andueza, M.-P.; Alignani, D.; Labiano, S.; Azpilikueta, A.; Rodriguez-Paulete, A.; et al. Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clin. Cancer Res. 2016, 22, 3924–3936. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bhattacharya, R.; Ye, X.C.; Wang, R.; Ling, X.; McManus, M.; Fan, F.; Boulbes, D.; Ellis, L.M. Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. Cancer Res. 2016, 76, 3014–3024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Samuel, S.; Fan, F.; Dang, L.H.; Xia, L.; Gaur, P.; Ellis, L.M. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 2010, 30, 1205–1212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mésange, P.; Poindessous, V.; Sabbah, M.; Escargueil, A.E.; de Gramont, A.; Larsen, A.K. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome bynintedanib, a small molecule angiokinase inhibitor. Oncotarget 2014, 5, 4709–4721. [Google Scholar] [CrossRef] [Green Version]
- Bhattacharya, R.; Fan, F.; Wang, R.; Ye, X.; Xia, L.; Boulbes, D.; Ellis, L.M. Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion. Br. J. Cancer 2017, 117, 848–855. [Google Scholar] [CrossRef] [Green Version]
- Mizukami, Y.; Jo, W.-S.; Duerr, E.-M.; Gala, M.; Li, J.; Zhang, X.; Zimmer, M.A.; Iliopoulos, O.; Zukerberg, L.R.; Kohgo, Y.; et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 2005, 11, 992–997. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Gao, J.; Wang, X.; Deng, S.; Ye, H.; Guan, W.; Wu, M.; Zhu, S.; Yu, Y.; Han, W. CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity. Cancer Biol. Ther. 2015, 16, 1775–1783. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.Y.; Battaglia, M.; Lee, S.H.; Sun, Q.H.; Aster, R.H.; Visentin, G.P. Platelet factor 4 differentially modulates CD4 + CD25 + (regulatory) versus CD4 + CD25-(nonregulatory) T cells. J. Immunol. 2005, 174, 2680–2686. [Google Scholar] [CrossRef] [Green Version]
- Wuyts, A.; Struyf, S.; Gijsbers, K.; Schutyser, E.; Put, W.; Conings, R.; Lenaerts, J.-P.; Geboes, K.; Opdenakker, G.; Menten, P.; et al. The CXC chemokine GCP-2/CXCL6 is predominantly induced in mesenchymal cells by interleukin-1β and is down-regulated by interferon-γ: Comparison with interleukin-8/CXCL8. Lab. Investig. 2003, 83, 23–34. [Google Scholar] [CrossRef] [Green Version]
Medium and Time | Type of Stimulation | p-Value |
---|---|---|
McCoy’s 2 h | Ca_Serum | 0.014 |
Nor_Serum | 0.004 | |
McCoy’s 4 h | Ca_Serum | 0.019 |
Nor_Serum | 0.023 | |
McCoy’s 6 h | Ca_Serum | 0.000 |
Nor_Serum | 0.000 |
Medium and Time | Type of Stimulation | Mean Difference | p-Value |
---|---|---|---|
McCoy’s 2 h | Ca_Serum | −28.729202 * | 0.001 |
Nor_Serum | −290.058917 * | 0.001 | |
McCoy’s 4 h | Ca_Serum | −23.142217 * | 0.001 |
Nor_Serum | −26.488188 * | 0.001 | |
McCoy’s 6 h | Ca_Serum | −8.049175 | 0.213 |
Nor_Serum | −3.654608 | 0.710 | |
McCoy’s 12 h | Ca_Serum | −25.851839 * | 0.002 |
Nor_Serum | −24.495701 * | 0.003 | |
acCoy’s 24 h | Ca_Serum | −28.196170 * | 0.004 |
Nor_Serum | −23.976026 * | 0.007 |
Medium and Time | Type of Stimulation | Mean Difference | p-Value |
---|---|---|---|
McCoy’s 24 h | Ca_Serum | −1.350560 * | 0.001 |
Nor_Serum | −2.100735 * | 0.000 | |
Ca_Serum 24 h | Nor_Serum | −0.750176 * | 0.007 |
MacCoy’s | 1.350560 * | 0.001 |
Medium and Time | Type of Stimulation | Mean Difference | p-Value |
---|---|---|---|
Ca_Serum 4 h | Nor_Serum | 2.945237 * | 0.044 |
MEM | 3.498874 * | 0.025 | |
MEM 6 h | Ca_Serum | −2.963012 * | 0.034 |
Nor_Serum | −5.099393 * | 0.005 |
Medium and Time | Type of Stimulation | Mean Difference | p-Value |
---|---|---|---|
MEM 4 h | Ca_Serum | −40.393690 * | 0.000 |
Nor_Serum | −25.335775 * | 0.001 | |
MEM 6 h | Ca_Serum | −33.842377 * | 0.000 |
Nor_Serum | −32.923005 * | 0.000 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
George, E.; Andrew, M.; Maria, T.; Argyro, V.; Elias, K. Angiodrastic Chemokines Production by Colonic Cancer Cell Lines. Onco 2022, 2, 69-84. https://doi.org/10.3390/onco2020006
George E, Andrew M, Maria T, Argyro V, Elias K. Angiodrastic Chemokines Production by Colonic Cancer Cell Lines. Onco. 2022; 2(2):69-84. https://doi.org/10.3390/onco2020006
Chicago/Turabian StyleGeorge, Emmanouil, Moursellas Andrew, Tzardi Maria, Voumvouraki Argyro, and Kouroumalis Elias. 2022. "Angiodrastic Chemokines Production by Colonic Cancer Cell Lines" Onco 2, no. 2: 69-84. https://doi.org/10.3390/onco2020006